Business
FY 2024 Results - Strong Revenue Growth
FY 2024 Results - Strong Revenue Growth.
About this update from Diaceutics Plc
[{"type":"text","content":"\n\nDiaceutics FY 2024 Results\n \nRevenue growth of 39% on a constant currency basis to £32.2 million in FY 2024\n \nRecord FY 2024 Adjusted EBITDA* growth of 50% to £4.2 million\n \nVery strong commercial momentum delivered in FY 2024 has continued into 2025 to date\n \nOrder book of £24.9 million and ARR of £16.8 million at 31 December 2024 provides good visibility for continued strong growth in 2025\n \n23% growth in number of customer therapeutic brands working with and three new customer enterprise-wide engagements added in FY 2024\n \nSuccessfully launched PMx solution\n \nStrong balance sheet with cash of £12.7 million\n \nIncreased sales presence in US during FY 2024 and opened US HQ in January 2025\n \nNew York, Belfast and London, 13 May 2025 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, today announces the continued strong performance and growth across its business for the year ended 31 December 2024.\n \nRyan Keeling, Diaceutics' Chief Executive Officer, commented: \"I am extremely pleased to report that 2024 was another strong year of performance and continued growth across our business. The investments we have made in sales and product innovation are showing returns ahead of plan and the team have executed well. This continued growth demonstrates the significant value our customers place on our solutions, reflected by the increasing number of therapeutic brands we are working with, and enterprise-wide engagements secured to date. We are mindful of the current macro-economic uncertainty and we are closely monitoring how this could impact our customers, but our strong commercial progress, delivered over the past two years during our accelerated investment in the business, has provided us with the solid foundation required to continue our impressive organic growth, and we expect to return to profitability in 2025.\"\n \nFinancial Highlights:\n\n\n\n\n· \n\n\nVery strong financial and commercial momentum delivered in FY 2024 including successful launch of PMx solution, which has continued into 2025\n\n\n\n\n· \n\n\nOrder book of £24.9 million at 31 December 2024 (£26.5 million at 31 December 2023) and Annual Recurring Revenue (ARR) of £16.8 millio...